Enanta Pharmaceuticals (ENTA) Total Current Liabilities (2012 - 2026)
Enanta Pharmaceuticals posted quarterly Total Current Liabilities of $46.4 million for Q1 2026, up 1.08% year-on-year from $45.9 million in Q1 2025, and up 3.83% on a QoQ basis from $44.7 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) has 15 years of Total Current Liabilities data on file, last reported at $46.4 million in Q1 2026.
- For the quarter ending Q1 2026, Total Current Liabilities rose 1.08% year-over-year to $46.4 million; the trailing twelve-month figure through Mar 2026 stood at $46.4 million (up 1.08% YoY), and the FY2025 full-year result was $48.6 million, down 15.61% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $46.4 million, up from $44.7 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $68.2 million in Q2 2023 and bottomed at $23.0 million in Q4 2022.
- The 5-year median for Total Current Liabilities is $46.4 million (2026), against an average of $46.0 million.
- The widest annual swing landed in 2022, when Total Current Liabilities plunged 39.3%; it then soared 196.02% in 2023.
- A 5-year view of Total Current Liabilities shows it stood at $23.0 million in 2022, then surged by 171.32% to $62.4 million in 2023, then declined by 21.4% to $49.0 million in 2024, then declined by 8.81% to $44.7 million in 2025, then increased by 3.83% to $46.4 million in 2026.
- The last three Total Current Liabilities figures came in at $46.4 million (Q1 2026), $44.7 million (Q4 2025), and $48.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.11 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - | 46.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 46.44 Mn |
| Dec 31, 2025 | 44.73 Mn |
| Sep 30, 2025 | 48.56 Mn |
| Jun 30, 2025 | 44.55 Mn |
| Mar 31, 2025 | 45.95 Mn |
| Dec 31, 2024 | 49.05 Mn |
| Sep 30, 2024 | 57.54 Mn |
| Jun 30, 2024 | 58.23 Mn |
| Mar 31, 2024 | 54.61 Mn |
| Dec 31, 2023 | 62.41 Mn |
| Sep 30, 2023 | 62.79 Mn |
| Jun 30, 2023 | 68.19 Mn |
| Mar 31, 2023 | 32.17 Mn |
| Dec 31, 2022 | 23.00 Mn |
| Sep 30, 2022 | 29.83 Mn |
| Jun 30, 2022 | 23.04 Mn |
| Mar 31, 2022 | 30.74 Mn |
| Dec 31, 2021 | 37.89 Mn |
| Sep 30, 2021 | 36.17 Mn |
| Jun 30, 2021 | 28.62 Mn |
| Mar 31, 2021 | 26.62 Mn |
| Dec 31, 2020 | 23.04 Mn |
| Sep 30, 2020 | 24.16 Mn |
| Jun 30, 2020 | 23.91 Mn |
| Mar 31, 2020 | 19.52 Mn |
| Dec 31, 2019 | 19.14 Mn |
| Sep 30, 2019 | 22.61 Mn |
| Jun 30, 2019 | 20.50 Mn |
| Mar 31, 2019 | 20.49 Mn |
| Dec 31, 2018 | 22.63 Mn |
| Sep 30, 2018 | 16.03 Mn |
| Jun 30, 2018 | 14.03 Mn |
| Mar 31, 2018 | 17.12 Mn |
| Dec 31, 2017 | 19.22 Mn |
| Sep 30, 2017 | 20.98 Mn |
| Jun 30, 2017 | 11.12 Mn |
| Mar 31, 2017 | 9.15 Mn |
| Dec 31, 2016 | 6.43 Mn |
| Sep 30, 2016 | 7.89 Mn |
| Jun 30, 2016 | 9.57 Mn |
| Mar 31, 2016 | 11.99 Mn |
| Dec 31, 2015 | 10.87 Mn |
| Sep 30, 2015 | 6.70 Mn |
| Jun 30, 2015 | 7.31 Mn |
| Mar 31, 2015 | 19.79 Mn |
| Dec 31, 2014 | 19.87 Mn |
| Sep 30, 2014 | 4.75 Mn |
| Jun 30, 2014 | 4.27 Mn |
| Mar 31, 2014 | 4.42 Mn |
| Dec 31, 2013 | 2.57 Mn |
| Sep 30, 2013 | 4.53 Mn |
| Jun 30, 2013 | 2.94 Mn |
| Mar 31, 2013 | 4.95 Mn |
| Sep 30, 2012 | 5.73 Mn |